ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1880

Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with First-Line Therapy: An Unexpected Scenario

Session Information

Category: Onco-Nephrology

  • 1500 Onco-Nephrology

Authors

  • Trevisani, Francesco, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Di marco, Federico, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Pani, Antonello, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Floris, Matteo, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Minnei, Roberto, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Scartozzi, Mario, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Cattaneo, Monica, Ospedale Luigi Sacco-Polo Universitario, Milano, Lombardia, Italy
  • Ghidini, Michele, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
Background

Immune checkpoint inhibitors (ICIs) and platinum-based chemotherapy (CT) are possible options for the palliative treatment of metastatic non-small cell lung cancer (NSCLC). Recently, CT in combination with immune- checkpoint inhibitors has become the treatment of choice for this setting of patients(pts). Aim of our study was to compare the nephrotoxic effect of both ICIs and CT in a cohort of metastatic NSCLC pts.

Methods

A consecutive cohort of 292 pts treated in first-line for NSLCL with immunotherapy or CT was enrolled in a multicentric trial between 2018-2021. eGFR (using CKD-EPI formula 2009) was detected at baseline and after each cycle of therapy to determine AKI and CKD onset according to K-DIGO criteria. Comparison between numerical variables was performed using linear regressions between groups using Kruskal-Wallis rank sum test for numerical variables and Pearson’s Chi square test for categorical variables.

Results

Clinical and pathological characteristics are reported in table 1. In terms of eGFR decay and CKD onset during the treatment cycle, no significative differences were observed (Figure 1). The same behaviour happened with AKI incidence over cycles (p=0.3) (Figure 2). Further analysis including clinical variables lead to the same results, suggesting that the nephrotoxicity of CT and immunotherapy could be considered overlap and not negligible.

Conclusion

Our study surprisingly highlights that both cisplatin/carboplatin-based CT and immunotherapy display a similar incidence of AKI and eGFR decay over time in NSLCL metastatic patients